Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Income Statement

Financials in millions USD. Fiscal year is September - August.

Year	2023	2022	2021	2020	2019
Revenue	0.23	0.26	0.72	0.31	0.22
Revenue Growth (YoY)	-11.43%	-64.66%	129.59%	41.41%	-48.62%
Cost of Revenue	0.03	0.07	0.18	0.1	0.02
Gross Profit	0.19	0.18	0.55	0.22	0.2
Selling, General & Admin	3.06	4.96	4.97	3.98	3.64
Research & Development	3.67	1.84	1.26	0.39	0.56
Other Operating Expenses	0	0	-1.52	0	0.14
Operating Expenses	6.73	6.8	4.71	4.36	4.34
Operating Income	-6.53	-6.62	-4.16	-4.15	-4.14
Other Expense / Income	0.18	0.76	0.02	-0.06	0.02
Pretax Income	-6.71	-7.38	-4.19	-4.08	-4.16
Net Income	-6.71	-7.38	-4.19	-4.08	-4.16
Preferred Dividends	-0.05	-0.11	-0.16	-0.15	-0.06
Net Income Common	-6.66	-7.27	-4.03	-3.93	-4.1
Shares Outstanding (Basic)	7	6	4	3	3
Shares Outstanding (Diluted)	7	6	4	3	3
Shares Change	12.38%	34.02%	58.34%	6.95%	9.63%
EPS (Basic)	-1.01	-1.24	-0.95	-1.47	-1.50
EPS (Diluted)	-1.01	-1.24	-0.95	-1.47	-1.50
Free Cash Flow	-5.91	-4.93	-3.99	-2.62	-3.65
Free Cash Flow Per Share	-0.89	-0.84	-0.91	-0.94	-1.41
Gross Margin	86.07%	71.87%	75.74%	68.43%	89.72%
Operating Margin	-2888.50%	-2591.67%	-576.16%	-1317.94%	-1860.64%
Profit Margin	-2946.36%	-2846.28%	-557.19%	-1249.71%	-1841.53%
Free Cash Flow Margin	-2614.84%	-1929.75%	-552.02%	-831.91%	-1640.42%
EBITDA	-6.52	-7.24	-4.03	-3.93	-4.1
EBITDA Margin	-2883.78%	-2833.68%	-557.69%	-1248.08%	-1840.83%
Depreciation & Amortization	0.19	0.15	0.16	0.16	0.06
EBIT	-6.71	-7.38	-4.19	-4.08	-4.16
EBIT Margin	-2967.41%	-2891.05%	-579.21%	-1297.56%	-1868.03%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).